Figure 1.
Analysis of SLAMF7high CD16− monocytes in the PB of HCs and MPN patients with MF. (A) To define SLAMF7highCD16− monocytes, we began by gating lymphocyte subsets in a forward scatter/side scatter dot plot. Subsequently, we gated CD14+CD66b− monocytes and divided them into SLAMF7highCD16−, SLAMF7lowCD16−, and CD16+ subsets. (B) The representative flow cytometry dot plot shows that the percentage of SLAMF7highCD16− monocytes increased in MPN patients with MF who harbored JAK2V617F compared with HCs. The ratios of the SLAMF7highCD16− subset to CD14+CD66b− monocytes are presented as percentages.